The vaccine proves safe in a small sample of human subjects, opening the way for the next phase of testing
A new colorectal cancer vaccine showed positive results in the phase 1 clinical trial to demonstrate that the approach is safe. The patients treated had no signs of serious adverse events and samples of their blood contained markers of immune activation — an early indication that the vaccine could activate immune cells to fight colorectal tumors and metastases. Further tests to determine if the vaccine is effective at slowing tumor growth are forthcoming.
The results were published in the Journal for ImmunoTherapy of Cancer.
Colon cancer, especially in younger people, is on the rise and is currently the second highest cause of cancer deaths in the US and worldwide. Surgery can cure the disease in many patients, but prognosis is poor for those with recurrence of their disease. If it proves effective in larger-scale trials the vaccine, developed by researchers at Jefferson (Philadelphia University + Thomas Jefferson University), could train the patient’s immune system to attack the colon cancer that had already spread before the surgery.
“There is an urgent need to understand what fuels colorectal cancer growth, and to harness that knowledge for developing novel therapies. This pivotal study provides some of the first evidence that it may be possible to safely direct a patient’s own immune system to seek and destroy this cancer type. This is a true milestone– made possible through the scientists and clinicians in our colorectal cancer team working in synchrony”, said Karen E. Knudsen, PhD, EVP of Oncology Services and Director of the Sidney Kimmel Cancer Center — Jefferson Health.
In earlier preclinical work in mice, Jefferson researchers demonstrated how the design of their vaccine worked. Tumor vaccines have historically been developed against a sort of molecular sign-post for cancer. Because they come from normal cells, cancer cells share nearly all of the same molecules, making it difficult for the immune system to differentiate normal from cancerous. Tumor antigens are molecules that the immune system can recognize as different from normal. In colorectal cancer, one such molecule called GUCY2C, was identified by Scott Waldman, MD, PhD, the Samuel M.V. Hamilton Professor and Director of the Gastrointestinal Cancer Program of the Sidney Kimmel Cancer Center — Jefferson Health.
The vaccine developed by first author, Adam Snook, PhD, Assistant Professor in the Department of Pharmacology and Experimental Therapeutics, Dr. Waldman and others, works by activating the immune system against the GUCY2C molecule. By joining the GUCY2C molecule with a molecule that boosts the immune reaction called PADRE, and loading it into an adenovirus vector, the researchers engineered a vaccine that could specifically target the colon cancer.
The current clinical trial enrolled 10 patients with stage I or II colon cancer. Patients were given one dose and came back for blood draws 30, 90, 180 days after immunization. Patients experienced some discomfort at the injection site, but reported no serious side effects of the vaccine. The blood samples showed activation of “killer T cells,” the immune cell type the researchers had expected. These killer T cells are responsible for finding and killing colon cancer cells that are responsible for causing the cancer to come back.
“We are preparing for a phase II study that will begin recruiting patients this fall,” says Dr. Snook. “We used lessons learned in the first study to modify the vaccine to hopefully make it even more effective.”
Since starting the trial, the researchers found that cancers other than colorectal cancer also express GUCY2C, including gastric, esophageal and pancreatic cancer. These are actually among the deadliest cancers. In fact, together with colorectal cancer, these four cancer types account for 20 percent of all cancer-related deaths.
“The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population,” says Dr. Snook.
The Latest on: Colorectal cancer vaccine
via Google News
The Latest on: Colorectal cancer vaccine
- Brazil Patent Allowance for Human Obesity Vaccines to Braasch Biotechon February 24, 2021 at 4:25 pm
New Patent for Therapeutic Vaccine Treatment for Obesity in humans. GARRETSON, SD, US, 2021 /EINPresswire.com/ -- Braasch Biotech LLC, an emerging biopharmaceutical company pioneering a new field of ...
- Need to register for a COVID vaccine by phone in the St. Louis area? There are hotlines for thaton February 24, 2021 at 11:46 am
If you’re having trouble navigating the internet to schedule a COVID vaccine appointment, or know someone without internet access, we’ve compiled a list of area hotlines serving the ...
- Cancer immunotherapy market is expected to grow CAGR of around 10.6% during the forecast period 2019 to 2026on February 24, 2021 at 3:55 am
The global cancer immunotherapy market is expected to grow at a noteworthy CAGR of around 10.6% during the forecast period 2019 to 2026 The Cancer Immunotherapy Market size is poised to hit around US$ ...
- Orioles' Trey Mancini Back On Field For Spring Training Nearly One Year After Cancer Diagnosison February 23, 2021 at 10:50 am
The Baltimore Orioles' Trey Mancini joined his teammates for spring training Monday nearly a year after he was diagnosed with colon cancer.
- Avian Influenza Vaccine Market Size to Cross USD 735.22 Million by 2025 at a CAGR of 7.25%, Predicts Market Research future (MRFR)on February 23, 2021 at 9:04 am
Avian Influenza Vaccine Market Overview: Market Research Future (MRFR) studied the Global Avian Influenza Vaccine Market ...
- Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancerson February 23, 2021 at 6:18 am
Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph-node targeting Amphiphile technology, announced it has ...
- COVID-19 vaccine: Cancer patients say they need to be next, and science is on their sideon February 19, 2021 at 12:34 pm
The pandemic now features jostling for position in line for a limited supply of vaccine, with research fresh off hospital floors on COVID-19.
- FDA Fast-Tracks Mesothelioma Vaccine Developmenton February 19, 2021 at 7:49 am
The FDA has fast-tracked development of ONCOS-102, an immunotherapy vaccine, following positive interim results in clinical trials.
- An mRNA vaccine delivered in hydrogel shows promise as a durable cancer immunotherapyon February 17, 2021 at 5:15 am
Scientists at China’s National center for Nanoscience and Technology have designed a hydrogel to deliver an mRNA vaccine with an immune-stimulating adjuvant. When injected into mice with melanoma, the ...
- 7 Steps To Reduce Your Risk Of Developing Canceron February 15, 2021 at 6:14 pm
Concerned about cancer prevention? Take charge by making changes such as eating a healthy diet and getting regular screenings.
via Bing News